Effect of denosumab or alendronic acid on the progression of aortic stenosis: A double-blind randomized controlled trial

Pawade, Tania A., Doris, Mhairi K., Bing, Rong, White, Audrey C., Forsyth, Laura, Evans, Emily, Graham, Catriona, Williams, Michelle C., van Beek, Edwin J R, Fletcher, Alison, Adamson, Philip D., Andrews, Jack P. M., Cartlidge, Timothy R. G., Jenkins, William S. A., Syed, Maaz, Fujisawa, Takeshi, Lucatelli, Christophe, Fraser, William, Ralston, Stuart H., Boon, Nicholas, Prendergast, Bernard, Newby, David E. and Dweck, Marc R. (2021) Effect of denosumab or alendronic acid on the progression of aortic stenosis: A double-blind randomized controlled trial. Circulation. ISSN 0009-7322

[img]
Preview
PDF (Accepted_Manuscript) - Accepted Version
Available under License Creative Commons Attribution.

Download (6MB) | Preview

Abstract

Background: Valvular calcification is central to the pathogenesis and progression of aortic stenosis, with pre-clinical and observational studies suggesting that bone turnover and osteoblastic differentiation of valvular interstitial cells are important contributory mechanisms. We aimed to establish whether inhibition of these pathways with denosumab or alendronic acid could reduce disease progression in aortic stenosis.  Methods: In a single-centre parallel group double-blind randomized controlled trial, patients over 50 years of age with calcific aortic stenosis (peak aortic jet velocity >2.5 m/s) were randomized 2:1:2:1 to denosumab (60 mg every 6 months), placebo injection, alendronic acid (70 mg once weekly) or placebo capsule. Participants underwent serial assessments with Doppler echocardiography, computed tomography aortic valve calcium scoring and 18F-sodium fluoride positron emission tomography and computed tomography. The primary endpoint was the calculated 24-month change in aortic valve calcium score.  Results: One-hundred and fifty patients (mean age 72±8 years; 21% female) with calcific aortic stenosis (peak aortic jet velocity 3.36 [2.93 to 3.82] m/s; aortic valve calcium score 1152 [655 to 2065] Agatston Units) were randomized and received the allocated trial intervention: denosumab (n=49), alendronic acid (n=51) and placebo (injection n=25, capsule n=25; pooled for analysis). Serum C-terminal telopeptide, a measure of bone turnover, halved from baseline to 6 months with denosumab (0.23 [0.18 to 0.33] to 0.11 [0.08 to 0.17] µg/L) and alendronic acid (0.20 [0.14 to 0.28] to 0.09 [0.08 to 0.13] µg/L) but was unchanged with placebo (0.23 [0.17 to 0.30] to 0.26 [0.16 to 0.31] µg/L). There were no differences in 24-month change in aortic valve calcium score between denosumab and placebo (343 [198 to 804] AU versus 354 [76 to 675] AU, p=0.41), or alendronic acid and placebo (326 [138 to 813] AU versus 354 [76 to 675] AU, p=0.49). Similarly, there were no differences in change in peak aortic jet velocity or 18F-sodium fluoride aortic valve uptake.  Conclusions: Neither denosumab nor alendronic acid affected progression of aortic valve calcification in patients with calcific aortic stenosis. Alternative pathways and mechanisms need to be explored to identify disease-modifying therapies for the growing population of patients with this potentially fatal condition.  Clinical Trial Registration: https://www.clinicaltrials.gov Unique Identifier: NCT02132026.

Item Type: Article
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: LivePure Connector
Date Deposited: 05 May 2021 00:03
Last Modified: 13 May 2021 16:23
URI: https://ueaeprints.uea.ac.uk/id/eprint/79918
DOI: 10.1161/CIRCULATIONAHA.121.053708

Actions (login required)

View Item View Item